Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in Mice

Journal of Immunotherapy

Volumn 36, Issue 2, 2013, Pages 124-132

  Wei, Shuang ^a   Egenti, Martin U ^a   Teitz Tennenbaum, Seagal ^a   Zou, Weiping ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

adoptive immunotherapy; radiation therapy; T regulatory cells

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN P 15095; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD11C; B-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPH NODES; MELANOMA; MICE; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873997540     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31828298e6     Document Type: Article

References (39)

1. North RJ. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother. 1984;16: 175-181.
2. Awwad M, North RJ. Radiosensitive barrier to T-cellmediated adoptive immunotherapy of established tumors. Cancer Res. 1990;50:2228-2233.
3. Chang AE, Shu SY, Chou T, et al. Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res. 1986;46:3426-3430.
4. Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med. 1990;171:249-263.
5. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550-4557.
6. Paulos CM, Kaiser A, Wrzesinski C, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res. 2007;13: 5280-5289.
7. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.
8. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000;96: 3838-3846.
9. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202:907-912.
10. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol. 2006;3:668-681.
11. Shu SY, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol. 1989;143:740-748.
12. Aruga A, Aruga E, Tanigawa K, et al. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol.159:; 1997:664-673.
13. Arca MJ, Krauss JC, Aruga A, et al. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 1996;3:39-47.
14. Arca MJ, Krauss JC, Strome SE, et al. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother. 1996;42:237-245.
15. Ito F, Carr A, Svensson H, et al. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model. J Immunother. 2003;26: 222-233.
16. Li Q, Furman SA, Bradford CR, et al. Expanded tumorreactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res. 1999;5:461-469.
17. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol. 1997;15:796-807.
18. Chang AE, Li Q, Jiang G, et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003;21:884-890.
19. Chang AE, Li Q, Bishop DK, et al. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther. 2000;11:839-850.
20. Teitz-Tennenbaum S, Li Q, Davis MA, et al. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother. 2009;32:602-612.
21. Teitz-Tennenbaum S, Li Q, Okuyama R, et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother. 2008;31:345-358.
22. Wei S, Shreiner AB, Takeshita N, et al. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res. 2008;68:5432-5438.
23. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10:942-949.
24. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J ExpMed. 1998;188:287-296.
25. Qu Y, Jin S, Zhang A, et al. Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice. Radiat Res. 2010;173:148-157.
26. Liu R, Xiong S, Zhang L, et al. Enhancement of antitumor immunity by low-dose total body irradiationis associated with selectively decreasing the proportion and number of T regulatory cells. Cell Mol Immunol. 2010;7:157-162.
27. Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010;33:1-7.
28. Kachikwu EL, Iwamoto KS, Liao YP, et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys. 2011;81:1128-1135.
29. Billiard F, Buard V, Benderitter M, et al. Abdominal gammaradiation induces an accumulation of function-impaired regulatory T cells in the small intestine. Int J Radiat Oncol Biol Phys. 2011;80:869-876.
30. Wasserman J, Blomgren H, Petrini B, et al. Effect of radiation therapy and in vitro X-ray exposure on lymphocyte subpopulations and their functions. Am J Clin Oncol. 1982;5:195-208.
31. Raben M, Walach N, Galili U, et al. The effect of radiation therapy on lymphocyte subpopulations in cancer patients. Cancer. 1976;37:1417-1421.
32. Gray WC, Chretien PB, Suter CM, et al. Effects of radiation therapy on T-lymphocyte subpopulations in patients with head and neck cancer. Otolaryngol Head Neck Surg. 1985;93: 650-660.
33. Cao M, Cabrera R, Xu Y, et al. Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells. Cell Biol Int. 2009;33:565-571.
34. Cao M, Cabrera R, Xu Y, et al. Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro. Int J Radiat Biol. 2011;87: 71-80.
35. Wang LX, Shu S, Plautz GE. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 2005;65:9547-9554.
36. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516-7523.
37. Takeshima T, Chamoto K, Wakita D, et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70:2697-2706.
38. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170: 6338-6347.
39. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64:4328-4337.